

Literaturverzeichnis

zum Titelthema „Erste Europäische Leitlinie zum Nebennieren-Inzidentalom“
von Dr. Timo Deutschbein und Professor Dr. Martin Fassnacht,
Bayerisches Ärzteblatt 4/2017, Seite 144 ff.

1. Grumbach MM, Biller BM, Braunstein GD et al. Management of the clinically inapparent adrenal mass (“incidentaloma”). *Ann Intern Med* 2003; 138: 424–429
2. Mansmann G, Lau J, Balk E et al. The clinically inapparent adrenal mass: update in diagnosis and management. *Endocr Rev* 2004; 25: 309–340
3. Fassnacht M, Arlt W, Bancos I et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. *Eur J Endocrinol* 2016; 175: G1–G34
4. Dinnes J, Bancos I, Ferrante di Ruffano L et al. Management of endocrine disease: Imaging for the diagnosis of malignancy in incidentally discovered adrenal masses: a systematic review and meta-analysis. *Eur J Endocrinol* 2016; 175: R51–R64
5. Debono M, Bradburn M, Bull M et al. Cortisol as a marker for increased mortality in patients with incidental adrenocortical adenomas. *J Clin Endocrinol Metab* 2014; 99: 4462–4470
6. Di Dalmazi G, Vicennati V, Garelli S et al. Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing's syndrome: a 15-year retrospective study. *Lancet Diabetes Endocrinol* 2014; 2: 396–405
7. Cawood TJ, Hunt PJ, O'Shea D, Cole D & Soule S. Recommended evaluation of adrenal incidentalomas is costly, has high falsepositive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink? *European Journal of Endocrinology* 2009 161 13–527.
8. Bancos I, Tamhane S, Shah M et al. Diagnosis of endocrine disease: The diagnostic performance of adrenal biopsy: a systematic review and meta-analysis. *Eur J Endocrinol* 2016; 175: R65–R80